JP2021519786A5 - - Google Patents

Info

Publication number
JP2021519786A5
JP2021519786A5 JP2020552869A JP2020552869A JP2021519786A5 JP 2021519786 A5 JP2021519786 A5 JP 2021519786A5 JP 2020552869 A JP2020552869 A JP 2020552869A JP 2020552869 A JP2020552869 A JP 2020552869A JP 2021519786 A5 JP2021519786 A5 JP 2021519786A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
hydrogen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519786A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024612 external-priority patent/WO2019191451A1/en
Publication of JP2021519786A publication Critical patent/JP2021519786A/ja
Publication of JP2021519786A5 publication Critical patent/JP2021519786A5/ja
Pending legal-status Critical Current

Links

JP2020552869A 2018-03-30 2019-03-28 チエノピリミジノン化合物 Pending JP2021519786A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650922P 2018-03-30 2018-03-30
US62/650,922 2018-03-30
PCT/US2019/024612 WO2019191451A1 (en) 2018-03-30 2019-03-28 Thienopyrimidinone compounds

Publications (2)

Publication Number Publication Date
JP2021519786A JP2021519786A (ja) 2021-08-12
JP2021519786A5 true JP2021519786A5 (cg-RX-API-DMAC7.html) 2022-04-04

Family

ID=66102328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552869A Pending JP2021519786A (ja) 2018-03-30 2019-03-28 チエノピリミジノン化合物

Country Status (8)

Country Link
US (1) US10584133B2 (cg-RX-API-DMAC7.html)
EP (1) EP3774815A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021519786A (cg-RX-API-DMAC7.html)
CN (1) CN112313236A (cg-RX-API-DMAC7.html)
AU (1) AU2019243186A1 (cg-RX-API-DMAC7.html)
CA (1) CA3094988A1 (cg-RX-API-DMAC7.html)
TW (1) TW202003524A (cg-RX-API-DMAC7.html)
WO (1) WO2019191451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021105335A1 (en) * 2019-11-27 2021-06-03 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
MX2022012677A (es) * 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
WO2022255890A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
US12662467B2 (en) 2022-04-18 2026-06-23 BioThery X, Inc. Isoindolinones, pharmaceutical compositions, and therapeutic applications

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334596A (en) 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CA2476583C (en) 2002-03-13 2011-07-05 Kristof Van Emelen Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
WO2005047293A1 (en) 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
TWI642670B (zh) 2010-09-14 2018-12-01 伊塞利克斯公司 Pi3k-德爾塔抑制劑以及其應用和生產方法
SI2683384T1 (sl) * 2011-03-11 2016-05-31 Celgene Corporation Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 mGluR1 길항제로 작용하는 사이에노피리미디논 유도체
WO2014172436A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
EP3399980B1 (en) * 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
CN109153644B (zh) * 2016-03-16 2022-10-21 H·李·莫菲特癌症中心研究有限公司 用以增强效应t细胞功能的针对cereblon的小分子
JP2020504711A (ja) * 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Similar Documents

Publication Publication Date Title
US12351582B2 (en) Aurora kinase inhibitors and uses thereof
JP2023508055A5 (cg-RX-API-DMAC7.html)
JP2018138577A5 (cg-RX-API-DMAC7.html)
JP2008525530A5 (cg-RX-API-DMAC7.html)
JP2022520448A5 (cg-RX-API-DMAC7.html)
JP2023123854A5 (cg-RX-API-DMAC7.html)
JP2023540228A5 (cg-RX-API-DMAC7.html)
JP2008528467A5 (cg-RX-API-DMAC7.html)
JP2016523973A5 (cg-RX-API-DMAC7.html)
JP2015533177A5 (cg-RX-API-DMAC7.html)
JP2020521741A5 (cg-RX-API-DMAC7.html)
JP2022520811A5 (cg-RX-API-DMAC7.html)
JP2021529812A5 (cg-RX-API-DMAC7.html)
JP2023504147A5 (cg-RX-API-DMAC7.html)
RU2011125376A (ru) Способ получения соединений дигидроинденамида, фармацевтические композиции, содержащие данные соединения, и их применение в качестве ингибитора протеинкиназы
JP2022526266A5 (cg-RX-API-DMAC7.html)
JP2013525458A5 (cg-RX-API-DMAC7.html)
JP2005514420A5 (cg-RX-API-DMAC7.html)
JP2013531055A5 (cg-RX-API-DMAC7.html)
US20140275016A1 (en) N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities
JP2020506895A5 (cg-RX-API-DMAC7.html)
RU2010145463A (ru) Производные замещенного 2-фенилпиридина
JP2014520108A5 (cg-RX-API-DMAC7.html)
JP2023533203A5 (cg-RX-API-DMAC7.html)
JP2019505595A5 (cg-RX-API-DMAC7.html)